There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy, Medicine

Comments

Comment on this article

Cited by 2

PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers
Authors: Mekonnen Sisay, Dumessa Edessa
Highlights from the Gynecologic Oncology Track at the 2017 Annual Meeting of the American Society of Clinical Oncology
Authors: Juliet E. Wolford, Krishnansu Tewari

See all cited by

The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC)

Read this article at

Related collections

Karger: Oncology

Comments

Comment on this article

Similar content 2,604

Cited by 2